Literature DB >> 22573144

Monte Carlo feature selection and rule-based models to predict Alzheimer's disease in mild cognitive impairment.

Marcin Kruczyk1, Henrik Zetterberg, Oskar Hansson, Sindre Rolstad, Lennart Minthon, Anders Wallin, Kaj Blennow, Jan Komorowski, Mats Gunnar Andersson.   

Abstract

The objective of the present study was to evaluate a Monte Carlo feature selection (MCFS) and rough set Rosetta pipeline for generating rule-based models as a tool for comprehensive risk estimates for future Alzheimer's disease (AD) in individual patients with mild cognitive impairment (MCI). Risk estimates were generated on the basis of age, gender, Mini-Mental State Examination scores, apolipoprotein E (APOE) genotype and the cerebrospinal fluid (CSF) biomarkers total tau (T-tau), phospho-tau(181) (P-tau) and the 42 amino acid form of amyloid β (Aβ42) in two sets of longitudinally followed MCI patients (n = 217 in total). The predictive model was created in Rosetta, evaluated with the standard tenfold cross-validation approach and tested on an external set. Features were ranked and selected by the MCFS algorithm. Using the combined pipeline of MCFS and Rosetta, it was possible to predict AD among patients with MCI with an area under the receiver operating characteristics curve of 0.92. Risk estimates were produced for the individual patients and showed good correlation with actual diagnosis in cross validation, and on an external dataset from a new study. Analysis of the importance of attributes showed that the biochemical CSF markers contributed the most to the predictions, and that added value was gained by combining several biochemical markers. Despite a correlation with the biochemical markers, the genetic marker APOE ε4 did not contribute to the predictive power of the model.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22573144     DOI: 10.1007/s00702-012-0812-0

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  26 in total

Review 1.  Mild cognitive impairment.

Authors:  Serge Gauthier; Barry Reisberg; Michael Zaudig; Ronald C Petersen; Karen Ritchie; Karl Broich; Sylvie Belleville; Henry Brodaty; David Bennett; Howard Chertkow; Jeffrey L Cummings; Mony de Leon; Howard Feldman; Mary Ganguli; Harald Hampel; Philip Scheltens; Mary C Tierney; Peter Whitehouse; Bengt Winblad
Journal:  Lancet       Date:  2006-04-15       Impact factor: 79.321

2.  Combined 99mTc-ECD SPECT and neuropsychological studies in MCI for the assessment of conversion to AD.

Authors:  B Borroni; D Anchisi; B Paghera; B Vicini; N Kerrouche; V Garibotto; A Terzi; L A Vignolo; M Di Luca; R Giubbini; A Padovani; D Perani
Journal:  Neurobiol Aging       Date:  2005-03-24       Impact factor: 4.673

3.  FDG-PET measurement is more accurate than neuropsychological assessments to predict global cognitive deterioration in patients with mild cognitive impairment.

Authors:  Gaël Chételat; Francis Eustache; Fausto Viader; Vincent De La Sayette; Alice Pélerin; Florence Mézenge; Didier Hannequin; Benoît Dupuy; Jean-Claude Baron; Béatrice Desgranges
Journal:  Neurocase       Date:  2005-02       Impact factor: 0.881

4.  Pinpointing plaques with PIB.

Authors:  Kaj Blennow; Henrik Zetterberg
Journal:  Nat Med       Date:  2006-07       Impact factor: 53.440

5.  A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's disease.

Authors:  N A Verwey; W M van der Flier; K Blennow; C Clark; S Sokolow; P P De Deyn; D Galasko; H Hampel; T Hartmann; E Kapaki; L Lannfelt; P D Mehta; L Parnetti; A Petzold; T Pirttila; L Saleh; A Skinningsrud; J C V Swieten; M M Verbeek; J Wiltfang; S Younkin; P Scheltens; M A Blankenstein
Journal:  Ann Clin Biochem       Date:  2009-04-02       Impact factor: 2.057

6.  Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects.

Authors:  Leslie M Shaw; Hugo Vanderstichele; Malgorzata Knapik-Czajka; Christopher M Clark; Paul S Aisen; Ronald C Petersen; Kaj Blennow; Holly Soares; Adam Simon; Piotr Lewczuk; Robert Dean; Eric Siemers; William Potter; Virginia M-Y Lee; John Q Trojanowski
Journal:  Ann Neurol       Date:  2009-04       Impact factor: 10.422

7.  Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment.

Authors:  H Hampel; S J Teipel; T Fuchsberger; N Andreasen; J Wiltfang; M Otto; Y Shen; R Dodel; Y Du; M Farlow; H-J Möller; K Blennow; K Buerger
Journal:  Mol Psychiatry       Date:  2004-07       Impact factor: 15.992

8.  Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study.

Authors:  Pieter Jelle Visser; Frans Verhey; Dirk L Knol; Philip Scheltens; Lars-Olof Wahlund; Yvonne Freund-Levi; Magda Tsolaki; Lennart Minthon; Asa K Wallin; Harald Hampel; Katharina Bürger; Tuula Pirttila; Hilkka Soininen; Marcel Olde Rikkert; Marcel M Verbeek; Luiza Spiru; Kaj Blennow
Journal:  Lancet Neurol       Date:  2009-06-10       Impact factor: 44.182

9.  Intra-individual stability of CSF biomarkers for Alzheimer's disease over two years.

Authors:  Henrik Zetterberg; Mona Pedersen; Karin Lind; Maria Svensson; Sindre Rolstad; Carl Eckerström; Steinar Syversen; Ulla-Britt Mattsson; Christina Ysander; Niklas Mattsson; Arto Nordlund; Hugo Vanderstichele; Eugeen Vanmechelen; Michael Jonsson; Ake Edman; Kaj Blennow; Anders Wallin
Journal:  J Alzheimers Dis       Date:  2007-11       Impact factor: 4.472

10.  Computational Analysis of Molecular Interaction Networks Underlying Change of HIV-1 Resistance to Selected Reverse Transcriptase Inhibitors.

Authors:  Marcin Kierczak; Michał Dramiński; Jacek Koronacki; Jan Komorowski
Journal:  Bioinform Biol Insights       Date:  2010-12-12
View more
  6 in total

Review 1.  Mini-Mental State Examination (MMSE) for the detection of Alzheimer's disease and other dementias in people with mild cognitive impairment (MCI).

Authors:  Ingrid Arevalo-Rodriguez; Nadja Smailagic; Marta Roqué I Figuls; Agustín Ciapponi; Erick Sanchez-Perez; Antri Giannakou; Olga L Pedraza; Xavier Bonfill Cosp; Sarah Cullum
Journal:  Cochrane Database Syst Rev       Date:  2015-03-05

2.  Mini-Mental State Examination (MMSE) for the early detection of dementia in people with mild cognitive impairment (MCI).

Authors:  Ingrid Arevalo-Rodriguez; Nadja Smailagic; Marta Roqué-Figuls; Agustín Ciapponi; Erick Sanchez-Perez; Antri Giannakou; Olga L Pedraza; Xavier Bonfill Cosp; Sarah Cullum
Journal:  Cochrane Database Syst Rev       Date:  2021-07-27

3.  Ciruvis: a web-based tool for rule networks and interaction detection using rule-based classifiers.

Authors:  Susanne Bornelöv; Simon Marillet; Jan Komorowski
Journal:  BMC Bioinformatics       Date:  2014-05-12       Impact factor: 3.169

Review 4.  Alzheimer's disease--subcortical vascular disease spectrum in a hospital-based setting: Overview of results from the Gothenburg MCI and dementia studies.

Authors:  Anders Wallin; Arto Nordlund; Michael Jonsson; Kaj Blennow; Henrik Zetterberg; Annika Öhrfelt; Jacob Stålhammar; Marie Eckerström; Mårten Carlsson; Erik Olsson; Mattias Göthlin; Johan Svensson; Sindre Rolstad; Carl Eckerström; Maria Bjerke
Journal:  J Cereb Blood Flow Metab       Date:  2016-01       Impact factor: 6.200

5.  Predicting progression of mild cognitive impairment to dementia using neuropsychological data: a supervised learning approach using time windows.

Authors:  Telma Pereira; Luís Lemos; Sandra Cardoso; Dina Silva; Ana Rodrigues; Isabel Santana; Alexandre de Mendonça; Manuela Guerreiro; Sara C Madeira
Journal:  BMC Med Inform Decis Mak       Date:  2017-07-19       Impact factor: 2.796

6.  Analysis of Expression Pattern of snoRNAs in Different Cancer Types with Machine Learning Algorithms.

Authors:  Xiaoyong Pan; Lei Chen; Kai-Yan Feng; Xiao-Hua Hu; Yu-Hang Zhang; Xiang-Yin Kong; Tao Huang; Yu-Dong Cai
Journal:  Int J Mol Sci       Date:  2019-05-02       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.